Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05029336 · ClinicalTrials.gov registry record · Phase 2

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

A Phase 2 study of Systemic Lupus Erythematosus and Systemic Sclerosis, sponsored by Stephan Grupp MD PhD.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT05029336: Recruiting Phase 2 study of Systemic Lupus Erythematosus and Systemic Sclerosis, sponsored by Stephan Grupp MD PhD.

NCT05029336 is a Phase 2 study of Systemic Lupus Erythematosus and Systemic Sclerosis that is actively recruiting participants, run by Stephan Grupp MD PhD. The registered enrollment target is 20 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05029336, a Phase 2 study of Systemic Lupus Erythematosus and Systemic Sclerosis, is actively recruiting participants, sponsored by Stephan Grupp MD PhD.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a treatment strategy capable of purging the pathogenic, autoreactive immune system and an opportunity for "immune reset." This strategy has been used in adults across a myriad of indications with evidence for efficacy. This study proposes a pilot study to evaluate this therapeutic strategy in children and young adults with systemic sclerosis (SSc) and systemic lupus erythematosis (SLE), two potentially life threatening autoimmune diseases that may response to this therapeutic approach.

Primary Outcome

Survival without evidence of relapse or disease progression

Conditions Studied

Systemic Lupus Erythematosus Systemic Sclerosis

Interventions

  • BIOLOGICAL Depletion of CD3/CD19 in an autologous stem cell transplant

Study Locations (1)

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-03
Est. Completion 2031-05
Phase Phase 2
Stephan Grupp MD PhD

8 total trials

What NCT05029336 shows while recruiting

NCT05029336 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Depletion of CD3/CD19 in an autologous stem cell transplant is the first listed.

NCT05029336 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05029336 about?

NCT05029336 is a clinical study titled "Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases". A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a treatment strategy capable of purgin...

What is the current status of trial NCT05029336?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-03. Estimated completion is 2031-05.

What conditions does trial NCT05029336 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Systemic Sclerosis.

What interventions are being tested in trial NCT05029336?

The interventions under investigation include: Depletion of CD3/CD19 in an autologous stem cell transplant (BIOLOGICAL).

Who is sponsoring clinical trial NCT05029336?

This trial is sponsored by Stephan Grupp MD PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05029336 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05029336's enrollment target sits among peer trials

20 90th of 99 higher than 9 of 99 other Systemic Lupus Erythematosus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

More recruiting context for NCT05029336

Source: ClinicalTrials.gov NCT05029336, the US trial registry maintained by the National Library of Medicine. NCT05029336 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.